NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

In September 2025, Japan’s Zeon Corporation announced its acquisition of Curate Biosciences’ Deterministic Cell Separation (DCS™) IP and integration into Edge Precision’s micro-molding lines for ZEONEX®/ZEONOR® cyclo-olefin polymer (COP) cartridges.

This event completed the physical supply chain for Eden’s consumables.

Zeon now controls every layer of Eden’s cartridge architecture—the polymer chemistry, the precision tooling, and the deterministic microfluidic geometry that purifies monocytes with gentle, reproducible physics.

Please elaborate on the relationship, if any, between Zeon and NWBO - other than as unrelated supplier/consumer on the open market. This is not guarantee of supply to NWBO.